|
|
|
|
|
|
|
04.02.26 - 14:30
|
Will BioCryst′s ORLADEYO Hit The $1 Billion Sales Mark? (RTTNews)
|
|
|
Shares of BioCryst Pharmaceuticals Inc. (BCRX) are down over 40% from their 52-week high of $11.31, recorded last June, and trade around $6. The company's core marketed drug is ORLADEYO, a plasma kallikrein inhibitor approved for the prophylaxis of hereditary angioedema. Net product sales of ORLADEYO have increased steadily each year....
|
|
|
|
|
21.01.26 - 22:03
|
Astria Stockholders Vote to Approve Acquisition by BioCryst (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the “Merger”).
The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, whose mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Astria's lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Astria's second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis.
Cautionary Note Regarding Forward-Looking Statements
Statements included in t...
|
|
|
|
|
|
|
|
|
06.01.26 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of January 2, 2026, as inducements material to such employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.12.25 - 13:42
|
XFRA: BO1: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
BIOCRYST PHARMAC. DL-,01 BO1 US09058V1035
AB/FROM ONWARDS 12.12.2025 13:32 CET...
|
|
|
|
|
12.12.25 - 13:01
|
XFRA: BO1: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
BIOCRYST PHARMAC. DL-,01 BO1 US09058V1035 BAW/UFN...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
